SCHEMBL21332993

SCHEMBL21332993

COC(=O)c1cccc(Cn2ncc(C(=O)Cn3cc(C#C[Si](C)(C)C)ccc3=O)c2C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABHD6 Q9BV23 1/20 0.42
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPK10 P53779 1/20 0.40
ADORA2A P29274 3/20 0.39
ADORA1 P30542 2/20 0.39
TAS2R8 Q9NYW2 2/20 0.38
IDO1 P14902 1/20 0.37
LMNA P02545 1/20 0.36
CD74 P04233 1/20 0.36
MIF P14174 1/20 0.36
CYP4F2 P78329 2/20 0.36
CYP4A11 Q02928 2/20 0.36
TRPA1 O75762 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.34
LOXL2 Q9Y4K0 1/20 0.34
S1PR2 O95136 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
ADORA2B P29275 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21332974 0.86 CREBBP (0.41) KMT2ASMN1; SMN2TAS2R8S1PR2POLB
SCHEMBL21332960 0.85 KMT2A (0.44) ABHD6KMT2ASMN1; SMN2MAPK10ADORA2A
SCHEMBL31675001 0.85 KMT2A (0.44) ABHD6KMT2ASMN1; SMN2MAPK10ADORA2A
SCHEMBL21333089 0.81 PTGDR2 (0.39) KMT2ASMN1; SMN2LMNAS1PR2POLB
SCHEMBL30866462 0.80 KMT2A (0.40) KMT2ASMN1; SMN2ADORA2AADORA1TAS2R8
SCHEMBL21333082 0.80 KMT2A (0.40) KMT2ASMN1; SMN2ADORA2AADORA1TAS2R8
SCHEMBL21332669 0.76 KDM4E (0.43) KMT2ASMN1; SMN2LMNAS1PR2POLB
SCHEMBL21333151 0.76 KMT2A (0.53) ABHD6KMT2ASMN1; SMN2MAPK10ADORA2A
SCHEMBL21333435 0.75 KMT2A (0.42) KMT2ASMN1; SMN2ADORA2AADORA1IDO1
SCHEMBL30866465 0.75 KMT2A (0.42) KMT2ASMN1; SMN2ADORA2AADORA1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3762377-B1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF UNIV CORNELL (US) 2025-08-20 EP disclosed
US-11964960-B2 Pyridinone- and pyridazinone-based compounds and uses thereof CORNELL UNIVERSITY (US) 2024-04-23 US disclosed
EP-3762377-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF Cook, Timothy, H. (US) 2021-01-13 EP disclosed
US-20200407339-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE 2020-12-31 US disclosed
WO-2019173790-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF HLA TIMOTHY (US) 2019-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200407339-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF PTGER1, LOXL1, COL1A1 ABHD6 2783/4885KMT2A 4385/4885SMN1; SMN2 3979/4885
US-11964960-B2 Pyridinone- and pyridazinone-based compounds and uses thereof PTGER1, LOXL1, COL1A1 ABHD6 2783/4885KMT2A 4385/4885SMN1; SMN2 3979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.